Glow

What Glow is

Glow 70mg is a research pen that holds three peptides: GHK-Cu, BPC-157 and TB-500. No published study has tested the three together. Each one has been tested alone for decades, mostly in cells and animals. None of them has a controlled human trial behind it.

A peptide is a short chain of amino acids, the building blocks of protein. The three in Glow are not alike in structure:

• GHK-Cu is a chain of three amino acids that holds on to copper. Scientists have tested it for collagen building and for changes in how skin genes switch on and off. Collagen is the protein that gives skin its structure.
• BPC-157 is a lab-made chain of 15 amino acids. It has been tested widely for growing new blood vessels and for protecting tissue in many organs.
• TB-500 is a lab-made copy of one part of a natural protein called thymosin beta-4. That part controls actin, a protein cells use to move. TB-500 has been tested for cell movement and wound repair signals.

Why put them in one pen? Scientists who work on tissue repair have proposed that the three do separate jobs that do not overlap. GHK-Cu reshapes the scaffold between cells. BPC-157 grows blood vessels and shields cells. TB-500 helps cells travel. All three jobs feed into healing [10], [17], [22].

Nobody has put that idea to a direct test. The search for this guide found no peer-reviewed paper in which GHK-Cu, BPC-157 and TB-500 were given at once, at any dose or in any mix. So this guide covers each part on its own, for research and education only.

How much research there is

Each part has its own body of animal and cell studies. The mix has none.

Question	Answer
GHK-Cu	Animal and lab work only: fibroblasts and other cells in a dish, wounds in animals, and gene activity scans called microarrays. No controlled human trials were found [1], [19]
BPC-157	Animal and lab work only: mostly rodents with injured tissue, tendons or wounds, and mostly from one group of scientists. No controlled human trials were found [17], [25]
TB-500 and thymosin beta-4	Mostly animal studies of wounds and blood vessel growth. One small published case series in people, on venous ulcers [16]
Glow, all three at once	Nothing. No published study gave GHK-Cu, BPC-157 and TB-500 together
Kinds of study	Fibroblasts and blood vessel lining cells in a dish. Rodents and rabbits with wounds, tendon injuries or cornea injuries. Microarray gene scans. One human case series (thymosin, venous ulcers)
Checked by other labs	GHK-Cu: yes, collagen and gene results were repeated by many separate groups over several decades. BPC-157: less so, since most results come from the group that first studied it. Thymosin beta-4: yes, several separate labs repeated the blood vessel and wound results
Approval	All three are still experimental. None is approved by the FDA, the EMA or the MHRA, alone or combined

How it might work

The three peptides act through three separate routes. No published study has looked at whether those routes affect each other when all three peptides are present. Each route below comes from that peptide’s own studies.

GHK-Cu: rebuilding the scaffold

GHK-Cu is the three-part peptide glycyl-L-histidyl-L-lysine joined to a copper(II) ion.

• Collagen. In an early study, fibroblasts grown in a dish made more collagen with GHK-Cu than without it [1]. Fibroblasts are the cells that build connective tissue. Lab-made relatives of GHK also helped skin wounds heal, which fits that finding [2].
• Matrix. The extracellular matrix is the scaffold between cells. In healing wounds, GHK-Cu changed how much of two matrix ingredients was made: small proteoglycans and glycosaminoglycans [5].
• Genes. Later reviews summed up microarray studies, which scan the whole genome at once. They linked GHK-Cu to changed activity in a large number of human genes. Those genes are tied to tissue repair, antioxidant defense and calming inflammation. For that reason, scientists describe GHK-Cu as acting broadly on gene activity, not on one target [19], [22].
• Skin. A 2015 review tied its interest for skin research to several cell pathways. These include making collagen and elastin, antioxidant enzyme activity, and changes in genes that control inflammation [20].

BPC-157: blood vessels and cell protection

BPC-157 is stable and lab made. Its 15 amino acids copy part of a stomach-protecting protein first found in human stomach juice. One group has done most of the work on it: Sikiric and colleagues at the University of Zagreb. Over more than 20 years they tested it in many kinds of tissue injury.

• Scientists have proposed that it protects cells in a broad way. Studies reported that it helps draw blood vessels to an injury.
• It also seems to work together with the body’s usual vessel growth signals, such as VEGF and FGF. It does not replace them [23], [24].
• A 2010 review placed these effects under an idea called cytoprotection. That idea began as a theory about protecting the stomach lining and was stretched to cover injured tissue in general [17].
• A 2016 review looked at its proposed action along the link between the brain and the gut [21].

TB-500: actin and cell movement

Thymosin beta-4, or Tβ4, is a small natural protein made of 43 amino acids. In most mammal cells it is the main protein that holds loose actin units in reserve. By doing so, it controls how actin threads are built. Those threads let a cell change shape and move [6].

TB-500 is the name used in research writing, and by sellers, for a lab-made peptide that matches the actin-binding part of Tβ4. One study pinned that binding site down to a short stretch called LKKTETQ. In tests on blood vessel lining cells, that stretch alone was enough to spur vessel growth [9].

Cells must move before new blood vessels can form. Repair cells must also move to reach a wound. So scientists have proposed that actin control is the link that ties together vessel growth, the movement of skin cells and fibroblasts, and wound closing [4], [10].

What nobody has tested

Reviewers of each peptide have described roles that could fit together: matrix rebuilding, vessel growth with cell protection, and cell movement. But no study has checked how these three routes interact, or whether they do at all. Any claim in this guide that the mix makes biological sense is a guess drawn from three separate sets of studies. It is not a result from a study of the mix.

What the studies found

The results are sorted by peptide, because each was studied apart from the others.

GHK-Cu

• Collagen in a dish. Fibroblasts treated with GHK-Cu made more collagen than untreated ones. This is among the first published results on how the compound works [1].
• Wounds in animals. In rabbits, GHK-Cu put on the skin, alone or with zinc oxide, changed measures of open wound healing [12]. That work followed an earlier veterinary study of the same kind of skin treatment on open wounds with poor blood supply [8].
• Wound matrix. During healing, GHK-Cu changed the making of small proteoglycans and glycosaminoglycans in the matrix [5].
• Gene activity. Reviews of whole-genome microarray data tied GHK-Cu to activity changes in many human genes. The genes relate to tissue repair, antioxidant defense and inflammation control. The reviews present it as a broad influence on genes that matter for skin and tissue regrowth, not a one-target agent [15], [19], [20], [22].

BPC-157

• Tendon. In tendon samples and in live animals, BPC-157 was linked to better tendon healing. Tendon cells survived, moved and grew outward [18].
• Tendon to bone. In rats with a detached Achilles tendon, it helped the tendon heal back onto bone. It also countered the slower healing that corticosteroid drugs cause [13].
• Skin wounds. Healing wounds formed more granulation tissue, the new tissue that fills a wound, and collagen was better organized. This went along with changes in a gene called egr-1 [14]. In mice, BPC-157 applied at the site improved healing of skin wounds made with a CO2 laser [11].
• Blood vessels. Reviews of its vessel-growing action reported that it helps bring blood vessels to injured sites. They proposed that it works with normal growth factor signals, not instead of them. The reviews covered healing of bone, muscle, ligament, tendon and the gut [23], [24]. A 2019 review placed this work within research on soft tissue healing in muscles and joints [25].

TB-500 and thymosin beta-4

• Wound healing. Early research found that Tβ4 sped up wound healing in animals. That result is one of the reasons it was later studied as a repair peptide [3].
• Blood vessels. In a dish and in animals, Tβ4 helped vessel lining cells mature and helped vessels form [4]. Follow-up work traced this effect to the actin-binding site [9].
• Eye injury. In animals with an alkali burn to the cornea, Tβ4 was linked to better healing of the cornea and less inflammation [7].
• People. A published case series looked at thymosin treatment of venous ulcers in humans. It is one of the few data points for this peptide beyond animal wound studies. It was small, it was not randomized, and it was not a controlled trial [16].

The gap for the mix itself

No peer-reviewed study has given GHK-Cu, BPC-157 and TB-500 as a group. The search covered published papers and trial registries, and it found nothing at any ratio, dose or route. Every result above comes from one peptide studied by itself. Glow is an experimental research product in the full sense: it has never been the subject of a published study. A result from one part cannot be assumed to hold unchanged in a blend of all three.

Safety

What the studies of each part report

• GHK-Cu. Animal wound studies have generally found it well tolerated at the strengths tested. Those papers looked at healing, not at toxic effects in a planned way [8], [12].
• BPC-157. The group that first studied it describes it as well tolerated in the animals tested. That judgment comes mostly from the same group that wrote most of the papers [17], [21].
• Thymosin beta-4. Studies, including the one human case series, reported no major harmful effects in the settings tested. The human evidence is very small [16].

What is not known

• No controlled human trial has been published for any of the three peptides alone. None exists for Glow.
• No study has checked whether mixing the three changes the safety, the side effects, or the amount of any one part that reaches the body.
• For all three parts, the published papers lack planned toxicity testing, safety data across doses, and long-term safety data.
• BPC-157 has the weakest record of checks by outside groups, as the table above shows.
• No formal drug interaction study was found for any pair of these peptides or for all three.

Legal status in the US

• Not FDA approved. None of the three parts is approved by the FDA for any use, alone or combined. The same is true of the EMA in Europe and the MHRA in the UK.
• Sport rules differ by part. The World Anti-Doping Agency (WADA) Prohibited List names two of the three. BPC-157 is named under class S0, non-approved substances. S0 covers drug-like substances that no government health authority has approved for treating people. Thymosin beta-4 and its derivatives, TB-500 included, are named under class S2, which covers peptide hormones, growth factors, related substances and mimetics. GHK-Cu is not named on the WADA list. This is a note on the rules only. It says nothing about safety or about whether anything works.
• Research use. It is supplied strictly for laboratory research use.

Limits of the research

1. The mix has never been studied. Every result here comes from GHK-Cu, BPC-157 or TB-500 tested alone. None comes from the three given together.
2. No controlled human trials for any part. The evidence for all three is mostly from cells in a dish and from animals. At most, there is one small human case series, for thymosin beta-4 in wound care.
3. One main group for BPC-157. A large share of the BPC-157 papers come from a single research group. Outside checks are thinner than for the other two parts.
4. Different routes, doses and forms. The cited studies put the peptides on the skin, injected them at the site, or gave them to the whole body. They used fibroblasts in a dish, rodents, rabbits and a human case series. None used the exact product sold as Glow.
5. The reason for mixing is a guess. The case for the blend rests on the claim that three separately studied repair routes fit together. That has not been tested directly. It is a research hypothesis, not a proven result.
6. Cells and animals, not people. Most of the cited results come from lab dishes or animals. No controlled human trial shows that they carry over to people, for any part alone or for the mix.
7. Missing negative results. Bias in what gets published or reported cannot be ruled out. This applies most to BPC-157, where a small number of groups wrote most of the papers.

Each of the three peptides has decades of cell and animal studies. The pen that combines them has no studies at all.

References

Selected peer-reviewed references covering the three individual components (GHK-Cu, BPC-157, TB-500/thymosin beta-4), each verified against the CrossRef API before inclusion. No combination-specific references exist. Ordered by date of publication.

1. Maquart F, Pickart L, Laurent M, Gillery P, et al. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters, 238(2), 343–346. DOI: 10.1016/0014-5793(88)80509-x
2. Buffoni F, Dal Pozzo A (1995). Skin wound healing properties of synthetic analogues of the tripeptide GHK (Gly-His-Lys). Pharmacological Research, 31, 69. DOI: 10.1016/1043-6618(95)86534-9
3. Malinda K, Kleinman H, Sidhu G, Mani H, et al. (1999). Thymosin β4 Accelerates Wound Healing. Journal of Investigative Dermatology, 113(3), 364–368. DOI: 10.1046/j.1523-1747.1999.00708.x
4. Grant D, Rose W, Yaen C, Goldstein A, et al. (1999). Thymosin β4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis, 3(2), 125–135. DOI: 10.1023/A:1009041911493
5. Siméon A, Wegrowski Y, Bontemps Y, Maquart F (2000). Expression of Glycosaminoglycans and Small Proteoglycans in Wounds: Modulation by the Tripeptide-Copper Complex Glycyl-L-Histidyl-L-Lysine-Cu2+. Journal of Investigative Dermatology, 115(6), 962–968. DOI: 10.1046/j.1523-1747.2000.00166.x
6. Huff T, Müller C, Otto A, Netzker R, et al. (2001). β-Thymosins, small acidic peptides with multiple functions. International Journal of Biochemistry & Cell Biology, 33(3), 205–220. DOI: 10.1016/S1357-2725(00)00087-X
7. Sosne G, Szliter E, Barrett R, Kernacki K, et al. (2002). Thymosin Beta 4 Promotes Corneal Wound Healing and Decreases Inflammation in Vivo Following Alkali Injury. Experimental Eye Research, 74(2), 293–299. DOI: 10.1006/exer.2001.1125
8. Canapp S, Farese J, Schultz G, Gowda S, et al. (2003). The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 32(6), 515–523. DOI: 10.1111/j.1532-950x.2003.00515.x
9. Philp D, Huff T, Gho Y, Hannappel E, et al. (2003). The actin binding site on thymosin β4 promotes angiogenesis. The FASEB Journal, 17(14), 1–13. DOI: 10.1096/fj.03-0121fje
10. Goldstein A, Hannappel E, Kleinman H (2005). Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 11(9), 421–429. DOI: 10.1016/j.molmed.2005.07.004
11. Bilic M, Bumber Z, Blagaic A, Batelja L, et al. (2005). The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice. Burns, 31(3), 310–315. DOI: 10.1016/j.burns.2004.10.013
12. Cangul I, Gul N, Topal A, Yilmaz R (2006). Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Veterinary Dermatology, 17(6), 417–423. DOI: 10.1111/j.1365-3164.2006.00551.x
13. Krivic A, Anic T, Seiwerth S, Huljev D, et al. (2006). Achilles Detachment in Rat and Stable Gastric Pentadecapeptide BPC 157: Promoted Tendon-to-Bone Healing and Opposed Corticosteroid Aggravation. Journal of Orthopaedic Research, 24(5), 982–989. DOI: 10.1002/jor.20096
14. Tkalčević V, Čužić S, Brajša K, Mildner B, et al. (2007). Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. European Journal of Pharmacology, 570(1-3), 212–221. DOI: 10.1016/j.ejphar.2007.05.072
15. Pickart L (2008). The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition, 19(8), 969–988. DOI: 10.1163/156856208784909435
16. Guarnera G, De Rosa A, Camerini R, et al. (2010). The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences, 1194(1), 207–212. DOI: 10.1111/j.1749-6632.2010.05490.x
17. Sikiric P, Seiwerth S, Brcic L, Sever M, et al. (2010). Revised Robert’s Cytoprotection and Adaptive Cytoprotection and Stable Gastric Pentadecapeptide BPC 157. Possible Significance and Implications for Novel Mediator. Current Pharmaceutical Design, 16(10), 1224–1234. DOI: 10.2174/138161210790945977
18. Chang C, Tsai W, Lin M, Hsu Y, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780. DOI: 10.1152/japplphysiol.00945.2010
19. Pickart L, Vasquez-Soltero J, Margolina A (2014). GHK and DNA: Resetting the Human Genome to Health. BioMed Research International, 2014, 1–10. DOI: 10.1155/2014/151479
20. Pickart L, Vasquez-Soltero J, Margolina A (2015). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015, 1–7. DOI: 10.1155/2015/648108
21. Sikiric P, Seiwerth S, Rucman R, Kolenc D, et al. (2016). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology, 14(8), 857–865. DOI: 10.2174/1570159x13666160502153022
22. Pickart L, Margolina A (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 19(7), 1987. DOI: 10.3390/ijms19071987
23. Seiwerth S, Rucman R, Turkovic B, Sever M, et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design, 24(18), 1972–1989. DOI: 10.2174/1381612824666180712110447
24. Sikiric P, Rucman R, Turkovic B, Sever M, et al. (2018). Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Current Pharmaceutical Design, 24(18), 1990–2001. DOI: 10.2174/1381612824666180608101119
25. Gwyer D, Wragg N, Wilson S (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153–159. DOI: 10.1007/s00441-019-03016-8